QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Secures Investment to Back Clinical Research
Immuno-oncology-focused biotechnology company BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) recently secured support for its novel immunotherapy clinical research in the form of an equity investment of C$500,000 by the company’s recently appointed director, Jamieson Bondarenko (http://ibn.fm/yMQfi). A recent article includes a comment from Bondarenko regarding the investment, where he states, “The importance of accelerating this work is evidenced in efficacy data of BriaCell’s Phase I/IIa study of Bria-IMT and safety data of the Bria-IMT KEYTRUDA combination study in advanced breast cancer. There exists a unique opportunity to advance BriaCell’s remarkable achievements on behalf of breast cancer patients, survivors and deceased,…